Genfit's NASH key phase 3 data delayed

Genfit's NASH key phase 3 data delayed

Source: 
Fierce Biotech
snippet: 

Genfit’s shares were in the red Friday morning after the French biotech announced it was delaying a data readout for its potential blockbuster fatty liver hopeful elafibranor.